IMMIX BIOPHARMA INC (IMMX): Institutional Ownership
Hedge funds and institutional managers reporting a position in IMMX · Health Care. Based on the most recent 13F filing from each holder, sourced from SEC EDGAR.
Reported Holders
8
13F filers
Aggregate Value
$14.9M
Across holders
Last Price
$9.98
2026-06-26
Sector
Health Care
GICS
Holder activity3 new3 added2 reduced
| Manager⇅ | Type⇅ | Shares⇅ | Market Value▼ | % of Total⇅ | % of Portfolio⇅ | Action⇅ | QoQ Change⇅ | Quarter⇅ |
|---|---|---|---|---|---|---|---|---|
| ADAGE CAPITAL PARTNERS GP, L.L.C. CIK 0001165408 | Hedge Fund | 1.50M | $7.8M | 52.6% | 0.0% | New | — | Q4 2025 |
| MARSHALL WACE, LLP CIK 0001318757 | Hedge Fund | 277K | $2.5M | 16.9% | 0.0% | Reduced | $-7.0M | Q1 2026 |
| Qube Research & Technologies Ltd CIK 0001729829 | Hedge Fund | 188K | $1.7M | 11.5% | 0.0% | Added | +$1.3M | Q1 2026 |
| RENAISSANCE TECHNOLOGIES LLC CIK 0001037389 | Hedge Fund | 259K | $1.4M | 9.1% | 0.0% | Added | +$1.2M | Q4 2025 |
| Hudson Bay Capital Management LP CIK 0001393825 | Hedge Fund | 64K | $578K | 3.9% | 0.0% | Added | +$272K | Q1 2026 |
| CITADEL ADVISORS LLC CIK 0001423053 | Hedge Fund | 47K | $430K | 2.9% | 0.0% | Reduced | $-257K | Q1 2026 |
| Brevan Howard Capital Management LP CIK 0001512857 | Hedge Fund | 44K | $399K | 2.7% | 0.0% | New | — | Q1 2026 |
| BALYASNY ASSET MANAGEMENT LLC CIK 0001218710 | Hedge Fund | 13K | $67K | 0.5% | 0.0% | New | — | Q4 2025 |
New
Hedge Fund
$7.8M· 52.6% of total· 0.0% port· 1.50M sh· — QoQ· Q4 2025
Reduced
Hedge Fund
$2.5M· 16.9% of total· 0.0% port· 277K sh· $-7.0M QoQ· Q1 2026
Added
Hedge Fund
$1.7M· 11.5% of total· 0.0% port· 188K sh· +$1.3M QoQ· Q1 2026
Added
Hedge Fund
$1.4M· 9.1% of total· 0.0% port· 259K sh· +$1.2M QoQ· Q4 2025
Added
Hedge Fund
$578K· 3.9% of total· 0.0% port· 64K sh· +$272K QoQ· Q1 2026
Reduced
Hedge Fund
$430K· 2.9% of total· 0.0% port· 47K sh· $-257K QoQ· Q1 2026
New
Hedge Fund
$399K· 2.7% of total· 0.0% port· 44K sh· — QoQ· Q1 2026
New
Hedge Fund
$67K· 0.5% of total· 0.0% port· 13K sh· — QoQ· Q4 2025